Insights
Insights From Our Experts
Articles
Considering Commercial Success During Clinical Development: Maintaining a Global Perspective
Posted by Melissa Thompson, B.Sc., MBA , Mike Ryan , Adam Hardy , Ari Mendell, MSc, PhD , Joshua Gauci on December 6, 202112/6/21
Although commercial success is the ultimate goal of pharmaceutical research and development (R&D), many new treatments do not meet expectations and fail to achieve broad global reimbursement after initial regulatory approval., This causes therapies to underperform across international markets…
Client Story: An Ode to EVERSANA
At EVERSANA, putting our clients and patients first is at the forefront of everything we do. Recently, when EVERSANA ENGAGE’s Bausch & Lomb (B&L) team closed out their last event of their speaker series, they didn’t just…
WEBINAR: Reimagining the Patient Journey for Cell and Gene Therapies: Informing, Engaging and Empowering the Patient Population
Cell and gene therapies (CGTs) hold great life-saving and therapeutic advancement potential, but their complexity requires careful approach–starting with engaging and educating patient communities earlier. While the patient’s voice should be a guiding force throughout the…
BLOG: Segmenting Health Systems
The COVID-19 pandemic has separated health systems based on the impact of the pandemic on their staff, operations and finances. While many health systems have struggled in these areas, some have truly succeeded. This means that…
Breaking News: Updates on Digital Medicine Coding and Payment
Over the past several months, we have been following the activities of the American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) regarding coding and payment, respectively, for digital medicine products. Both…
EPP Keynote Address: Global Pricing and Market Access Hurdles for Innovation
Global Pricing and Market Access Hurdles for Innovation In a recent keynote address at the 2021 EPP Life Sciences Pricing Conference, Alan Crowther, General Manager, EVERSANA Pricing and Market Access, discusses 4 hurdles that are serving…
Promoting Treatment of the ‘Right’ Patient
Every treatment has a patient population that truly benefits from the intervention. This population starts with those targeted in the pivotal trials but typically grows from there based on real-world evidence (RWE) and prescriber experiences. At…
Pharma Europe 2021 : Panel
A Data and Digital Enabled GTM Strategy for Long-term Business Impact Rohit Sood, Executive Vice President, COMPLETE Commercialization, joined a panel of industry experts to discuss why an aligned and cross-functional go-to-market strategy has never been more…
Bio-Europe “Collaboration Close-Up”: Exploring the EVERSANA – Shorla Pharma Partnership
Launching in today’s unpredictable market is a journey with new challenges around every corner. While the oncology pipeline is rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build…
Telling the Whole Story: An Integrated Approach to Value Proposition Creation
Posted by Ellen Cappellino , Katya Svoboda , Jeff LaVaute , Melissa Thompson, B.Sc., MBA on November 2, 202111/2/21
Market shifts are underway, emphasizing the need for value propositions that are more seamless and integrated across functions. Adapting to these changes will be critical if manufacturers want to maximize pricing opportunities and avoid missing opportunities…